Breaking News
Friday , October 20 2017
Home / Tag Archives: Sun Pharmaceutical Industries

Tag Archives: Sun Pharmaceutical Industries

Sun Pharmaceutical Industries informs about company updates

Pursuant to the requirements of Regulation 44(3) of the SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015, Sun Pharmaceutical Industries has informed about the details of the result of remote e-voting, postal ballot and poll conducted at the NCLT convened meeting of equity shareholders of Sun Pharmaceutical Industries held on ... Read More »

Sun Pharma recalls 13,200 bottles of chewable Cetirizine from US market

Sun Pharmaceutical Industries is recalling over 13,200 bottles of antihistamine, Children’s Cetirizine Hydrochloride chewable tablets in the strength of 5 mg made at Halol plant, from the US market for failed specifications. The ongoing class III recall is nationwide in the USA and Puerto Rico. Sun Pharmaceutical Industries is an ... Read More »

USFDA accepts Sun Pharma’s application for Tildrakizumab

The US Food and Drug Administration (USFDA) has accepted Sun Pharmaceutical Industries’ Biologics License Application (BLA) for tildrakizumab. The USFDA filing acceptance follows the acceptance of the regulatory filing of tildrakizumab by the European Medicines Agency (EMA) in March 2017. Tildrakizumab is an investigational IL-23p19 inhibitor being evaluated for the ... Read More »